May Health

May Health is a clinical-stage medical device company based in Paris, France, focused on developing treatment options for women with Polycystic Ovary Syndrome (PCOS). Founded in 2017, the company was initially established as Ziva Medical and has since evolved under the leadership of experienced professionals in medtech and women's health.

The company's primary product, Ovarian Rebalancing™, is an investigational treatment aimed at restoring ovulation in women facing infertility due to PCOS. This innovative approach involves a one-time outpatient procedure that utilizes targeted ovarian ablation to reduce androgen production, eliminating the need for hormone-based treatments. May Health is currently conducting clinical studies, including the pivotal REBALANCE Study, to evaluate the therapy's effectiveness and safety, with plans to seek regulatory approval in the US and Europe.

May Health targets women suffering from PCOS and related infertility, addressing a condition that affects approximately 1 in 10 women globally. The company has secured significant funding to support its development and growth, enabling it to advance its clinical trials and bring its treatment to market.